ArticlePolish journal of microbiology2025
Antimicrobial Consumption in The Community Sector in Poland, 2019-2024: Changes and Challenges.
Article in Polish journal of microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative in vitro activity of furazidin and nitrofurantoin and assessment of resistance mechanisms in Escherichia coli isolates from urinary tract infections.Folia microbiologica · 2026Article
- Trend Analysis of Respiratory Disease Mortality in the Population Aged 65 and over in Poland: Results from a Registry Study (2000-2022).Advances in respiratory medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monitoring antibiotic consumption (AMC) in the community sector is essential for understanding prescribing patterns and informing national stewardship policies. This analysis presents recent trends in community antibiotic use in Poland from 2019 to 2024, focusing on temporal dynamics and progress toward the European Union's 2030 reduction targets. By 2030, there should be an overall reduction in AMC, with at least 65% of total AMC in humans accounted for by drugs from the WHO Access group, first- or second-line antibiotics for common infections with a narrower spectrum of action. Data on systemic antibacterials (ATC J01) were obtained from IQVIA Poland and expressed in defined daily doses per 1,000 inhabitants per day (DID). Antibiotic use in the community sector sharply declined in 2020 due to the COVID-19 pandemic, but then increased, surpassing pre-pandemic levels by 2022. By 2024, community consumption reached 21.2 DID, remaining significantly above the EU/EEA average. Penicillins (J01C) consistently accounted for the largest share of use, primarily due to broad-spectrum agents like amoxicillin-beta-lactamase inhibitor combinations (e.g., amoxicillin-clavulanic acid). The use of narrow-spectrum penicillins remained low. Macrolides (J01F) and cephalosporins and other beta-lactams (J01D) experienced a marked post-pandemic increase, while tetracyclines (J01A) and quinolones (J01M) remained relatively stable. In 2024, Access antibiotics comprised 57.3% total outpatient use, indicating that narrower-spectrum agents are underused in Poland. Our findings suggest that enhancing stewardship programs, improving access to microbiological diagnostic testing, and ensuring consistent adherence to infection-prevention measures will be crucial in achieving the EU and WHO 2030 goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.